

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

## بسم الله الرحمن الرحيم





MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

### جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



## ROLE OF FGF21 IN GESTATIONAL DIABETES MELLITUS IN A SAMPLE OF EGYPTIAN POPULATION

Thesis

Submitted for partial fulfillment of Master Degree in Internal Medicine

Presented by

**Ammar Ramadan Abdelrahman Ahmed** 

(M.B., B.Ch)

Supervised by

#### Prof. Dr. Inas Mohamed Sabry

Professor of Internal Medicine & Endocrinology Faculty of Medicine, Ain Shams University

#### Prof. Dr. Maram Mohamed Maher Mahdy

Professor of Internal Medicine & Endocrinology Faculty of Medicine, Ain Shams University

#### Dr. Mina Mikhail Nassim

Lecturer of Internal Medicine & Endocrinology
Faculty of Medicine, Ain Shams University
Faculty of Medicine
Ain Shams University
2021



# العلاقه بين تركيز عامل النمو ٢١ للخلايا الليفيه (GDM) ومرض الحمل السكري (GDM) يا عينه من المجتمع المصري

رسالة

توطئة للحصول على درجة ماجستير الباطنه العامه مقدمة من

الطبيب / عمار رمضان عبد الرحمن أحمد بكالوريوس الطب و الجراحة تحت إشراف

أ.د/ ايناس محمد صبري

أستاذ الباطنة العامة والغدد الصماء كلية الطب- جامعة عين شمس

أ.د/ مرام محمد ماهر مهدي

أستاذ الباطنة العامة والغدد الصماء كلية الطب- جامعة عين شمس

د/ مینا میخائیل نسیم

مدرس الباطنة العامة والغدد الصماء كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

7.71



سورة البقرة الآية: ٣٢



I am deeply thankful to Allah by the grace of whom, this work was possible.

I would like to express my deepest appreciation and gratitude to **Prof. Dr. Inas Mohamed Sabry**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain shams University, for her kind supervision, valuable advices and constructive guidance were the real driving force in the initiation progress and completion of this thesis.

I am greatly indebted to *Dr. Maram Mohamed Maher*, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, for the greatest and unforgettable help and for her valuable comments, suggestions and close supervision. She dedicated much of her effort and time for the direction of this work.

My sincerest and cardial thanks to *Dr. Mina Mikhail Nassim*, Lecturer of Internal Medicine & Endocrinology, Faculty of Medicine, Ain Shams University, for his valuable and great supervision and help in preparing, discussing and presenting this work in a satisfactory level.

Last and not least, I want to thank all my family, my colleagues, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed

Ammar Ramadan Abdelrahman Ahmed

#### **CONTENTS**

Tit	tle		Page
•	List of Abbro	eviations	I
•	List of Table		
•	List of Figures		
•	Introduction		1
•	Aim of the work		
•	Review of lit	terature	
	Chapter (1):	Gestational Diabetes Mellitus	4
	Chapter (2):	FGF21	35
	Chapter (3):	The link between FGF21 and Gestational DM	64
•	Patients and	l methods	74
•	Results	•••••	82
•	Discussion	•••••	106
•	Summary	••••••	117
•	Conclusions	•••••	120
•	Recommend	lations	121
•	References.	•••••	122
•	. الملخص العربي	••••••	

#### **LIST OF ABBREVIATIONS**

LIST OF ABBREVIATIONS			
Abb.		Full term	
BAT	:	Brown adipose tissue	
BAT	:	Brown Adipose Tissue	
<b>BMI</b>	:	Body Mass Index	
C-AMP	:	Cyclic adenosine Monophosphate	
CDA	:	Canadian Diabetes Association	
<b>ECM</b>	:	Extracellular Matrix	
ERK1/2	:	Extracellular signal- regulated protein kinases 1 & 2 activation.	
<b>FBG</b>	:	Fasting blood glucose	
GA	:	Gestational Age	
<b>GDM</b>	:	Gestational Diabetes Mellitus	
GLP-1	:	Glucagon like peptide-1	
HAPO	:	Hyperglycemia Adverse Pregnancy Outcomes	
HbA1c	:	Glusosylated Hemoglobin A1c	
HDL	:	High Density Lipoproteins	
Homa-IR	•	Homeostatic Model Assessment for Insulin	
***	•	Resistance	
HS	:	Heparan Sulfate	
i.c.v.	:	Intracerebroventricular	
IADPSG	:	International Association of Diabetes in Pregnancy Study Group	
LC n-3	:	Long-Chain n-3 Polyunsaturated fatty Acids	
LDL	:	Low Density Lipoproteins	
OGTT	:	Oral Glucose Tolerance Test	
PPAR-a	:	Peroxisome proliferator-activated receptor alfa	
<b>PPARg</b>	:	Peroxisome Proliferator Activated Receptor Gamma	
<b>PPGL</b>	:	Pheochromocytoma/functional paraganglioma	
RBP4	:	Retinol Binding Protein 4	
SCN	:	Supra- chiasmatic nucleus	
SHBG	:	Sex Hormone Binding Globulins	
<b>SMBG</b>	:	Self-monitoring of blood glucose	
T1DM	:	Type 1 Diabetes Mellitus	
T2DM	:	Type 2 Diabetes Mellitus	

#### &List of Abbreviations

Abb.	Full term
TG	: Triglycerides
<b>USPSTF</b>	: U.S. Preventive services Task Force
WAT	: White adipose tissue
$\mathbf{WT}$	: Wild Type page 7 chapter 2

#### **LIST OF TABLE**

Table No	<b>Subjects</b> Page	
<b>Table (1):</b>	Gene Variants associated with GDM12	
<b>Table (2):</b>	Summary of reported risk factors for GDM15	
<b>Table (3):</b>	Summary of selected careening strategies	
	recommending the use of risk factors for the	
	identification of gestational diabetes16	
<b>Table (4):</b>	Differences between Chinese and Caucasian	
	women with GDM ↑- increased in GDM; ↓-	
	decreased in GDM; ↔-no difference between	
	GDM and non GDM17	
<b>Table (5):</b>	Screening for and diagnosis of GDM19	
<b>Table (6):</b>	Serum FGF21 levels in different clinical	
	conditions39	
<b>Table (7):</b>	Most important hormones45	
<b>Table (8):</b>	Most important drugs45	
<b>Table (9):</b>	Most important nutritional activators46	
<b>Table (10):</b>	Demographic data of the study group (n=80):82	
<b>Table (11):</b>	Gestational age in the study group (n=80):83	
Table (12): I	Blood pressure of the study group (n=80):84	
<b>Table (13):</b>	FGF21 fasting level in the study group (n=80):85	
<b>Table (14):</b>	Blood glucose monitoring in the study group	
	(n=80):86	
<b>Table (15):</b>	Blood Insulin level in the study group (n=80):87	
<b>Table (16):</b>	Lipid profile of the study group (n=80):88	
<b>Table (17):</b>	Obstetric US at 24-28 weeks of gestational age in	
	the study group (n=80):89	
<b>Table (18):</b>	Family history of Diabetes mellitus in the study	
	group (n=80):	
Table (19): Comparing fasting FGF21 between two groups		
	of he study by ANOVA test:90	

#### ∠List of Table

Table No	<b>Subjects</b> Page		
<b>Table (20):</b>	Comparing demographic data between two		
	groups by ANOVA test:91		
<b>Table (21):</b>	Comparing blood glucose level between two		
	groups of the study by ANOVA test:92		
<b>Table (22):</b>	Comparing blood insulin level between two		
	groups of the study by ANOVA test:93		
<b>Table (23):</b>	Comparing lipid level between two groups of the		
	study by ANOVA test:94		
<b>Table (24):</b>	Comparing family history between two groups of		
	the study group by ANOVA test (n=80):95		
<b>Table (25):</b>	Pearson correlation (R) between fasting FGF21		
	and demographic data in the study group (n=80)96		
<b>Table (26):</b>	Pearson correlation (R) between fasting FGF21		
	and blood glucose level in the study group (n=80)98		
<b>Table (27):</b>	Pearson correlation (R) between fasting FGF21		
	and insulin level in the study group (n=80)100		
<b>Table (28):</b>	Pearson correlation (R) between fasting FGF21		
	and lipid profile in the study group (n=80)102		
<b>Table (29):</b>	Predictive value of fasting FGF21 for GDM by		
	Receiver Operating Characteristic (ROC) curve		
	analysis		

#### **LIST OF FIGURES**

Figure No	Subjects Page	e
Figure (1):	Pathogenic factors underlying GDM	10
Figure (2):	Classification of human fibroblast growth factors	
	into seven sub-classes.	35
Figure (3):	Mechanism of FGF21 action.	37
Figure (4):	Systemic and local actions of FGF 21, PPAR $\alpha$ =	
	peroxisome proliferator activated recptors $\alpha$	
	PPARγ = peroxisome proliferator-activated	
	receptors γ, TZDs = thiazolidinediones	38
<b>Figure (5):</b>	Endocrine, autocrine, and pharmacological	
	actions of FGF21.	41
Figure (6):	Changes in hepatic fat content and serum FGF21	
	level during the control and exercise periods	54
<b>Figure (7):</b>	A) Westem blot demonstrating FGF21protein	
	levels in placenta from macrosomic (LGA)	
	infants compared to placentas of appropriate for	
	gestational age (AGA) infants b) quantification of	
	FGF21 protein with 95% confidence intervals. C)	
	Western blot demonstrating PPARa protein levels	
	in samples from macrosomic (or LGA) infants	
	compared to AGA infants D) Quantification of	
	PPARa protein with 95% confidence intervials	67
Figure (8):	kib expression in the hypothalamus is essential	
	for FGF21 mediated effects on ovulation	68
Figure (9):		
	Westen blot in Cord blood serum from four	
	subjects (P1-P4). One preterm (P1) and three at	
	term (P2-P4). b) FGFR1 and β-klotho mRNA	
	expression in visceral adipose tissue (AT) and	
	crord tissue (CT)	70

Figure No	<b>Subjects</b> P	Page
<b>Figure (10):</b>	Column graph of mean age in the study group	82
<b>Figure (11):</b>	Column graph of mean gestational age in the	e
	study group	83
<b>Figure (12):</b>	Column graph of mean blood pressure in the	e
	study group	84
<b>Figure (13):</b>	Column graph of mean fasting FGF21 in the	2
	study group	85
<b>Figure (14):</b>	Column graph of mean blood glucose levels in	ı
	the study group	86
<b>Figure (15):</b>	Column graph of mean fasting insulin level in the	•
	study group	87
<b>Figure (16):</b>	Column graph of mean HOMA-IR level in the	•
	study group	87
<b>Figure (17):</b>	Column graph of mean lipid level in the study	7
	group	88
<b>Figure (18):</b>	Pie chart representing family history of diabetes	S
	in the study group	89
<b>Figure (19):</b>	Column graph comparing mean FGF21 level	
	between GDM and normal group	90
<b>Figure (20):</b>	Column graph comparing mean gestational age	2
	between GDM and normal group	91
<b>Figure (21):</b>	Column graph comparing mean blood glucose	
	levels between GDM and normal group	
<b>Figure (22):</b>	Column graph comparing mean insulin levels	S
	between GDM and normal group	
<b>Figure (23):</b>	Column graph comparing mean lipid level	
	between GDM and normal group	
<b>Figure (24):</b>	Column graph comparing distribution of family	
	history of diabetes between GDM and normal	l
	group	95

Figure No	Subjects	Page
<b>Figure (25):</b>	Pearson correlation, showing significant negat	tive
	correlation between fasting FGF21 level a	and
	gestational age (r -ve, P.< 0.05)	97
<b>Figure (26):</b>	Pearson correlation, showing significant posit	tive
	correlation between fasting FGF21 level a	and
	preganacy BMI(r +ve, P.< 0.05)	97
<b>Figure (27):</b>	Pearson correlation, showing significant posit	tive
	correlation between fasting FGF21 level a	and
	fasting blood glucose (r +ve, P.< 0.05)	99
<b>Figure (28):</b>	Pearson correlation, showing significant posit	tive
	correlation between fasting FGF21 level a	and
	HA1C% (r +ve, P.< 0.05)	99
<b>Figure (29):</b>	Pearson correlation, showing significant posit	tive
	orrelation between fasting FGF21 level a	and
	fasting insulin level (r +ve, P. $<$ 0.05)	101
<b>Figure (30):</b>	Pearson correlation, showing significant posit	tive
	correlation between fasting FGF21 level a	and
	HOMA-IR level (r +ve, P.< 0.05)	101
<b>Figure (31):</b>	Pearson correlation, showing significant posit	tive
	correlation between fasting FGF21 level and to	
	cholesterol level (r +ve, P.< 0.05).	
<b>Figure (32):</b>	Pearson correlation, showing significant posit	
	correlation between fasting FGF21 level and L	
	level (r +ve, P.< 0.05)	
<b>Figure (33):</b>	Receiver Operating Characteristic (ROC) cu	
	showing significant predictive value fast	_
	FGF21 for GDM at cut off > 115 ng/L, w	
	sensitivity 87.5 % and specificity 100 %	105